Living donor liver transplantation for hepatitis B associated liver diseases

A 10-year experience in a single center

Toru Ikegami, Yuji Soejima, Ryuji Ohta, Akinobu Taketomi, Tomoharu Yoshizumi, Noboru Harada, Hiroto Kayashima, Yoshihiko Maehara

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aims: Hepatic failure associated with hepatitis B virus (HBV) is one of the main indications for living donor liver transplantation (LDLT). Methodology: Twenty-nine LDLTs, including liver cirrhosis due to HBV (LC-B) (n=17) and fulminant hepatitis B (FH-B) (n=12) were reviewed. Prophylaxis for reinfection was performed with a combination of lamivudine, or hepatitis B immune globulin (HBIG) or adefovir, depending on the viral status. The changes in serological markers, recurrence and survival rate were examined. Results: There were 3 patients with re-emergencies of HBV surface antigen (HBsAg): suspension of HBIG for giving vaccination for HBV (n=1), HBsAg positive donor (n=1) and non-compliance for HBIG (n=1). All patients with YMDD mutants (n=9), except the case with HBsAg positive donor (n=1), were successfully protected by the triple therapy of lamivudine, adefovir and HBIG. No graft loss was due to the recurrence of HBV. Conclusion: The basic strategy using a combination of HBIG and antiviral agents gave acceptable long-term outcomes for LDLT for HBV associated liver diseases. The close monitoring of HBV viral status after transplantation is still crucial in managing these patients.

Original languageEnglish
Pages (from-to)1445-1449
Number of pages5
JournalHepato-Gastroenterology
Volume55
Issue number85
Publication statusPublished - Jul 1 2008

Fingerprint

Living Donors
antineoplaston A10
Hepatitis B
Hepatitis B virus
Liver Transplantation
Liver Diseases
Immunoglobulins
Lamivudine
Surface Antigens
Tissue Donors
Recurrence
Liver Failure
Hepatitis B Surface Antigens
Liver Cirrhosis
Antiviral Agents
Suspensions
Vaccination
Emergencies
Survival Rate
Transplantation

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Living donor liver transplantation for hepatitis B associated liver diseases : A 10-year experience in a single center. / Ikegami, Toru; Soejima, Yuji; Ohta, Ryuji; Taketomi, Akinobu; Yoshizumi, Tomoharu; Harada, Noboru; Kayashima, Hiroto; Maehara, Yoshihiko.

In: Hepato-Gastroenterology, Vol. 55, No. 85, 01.07.2008, p. 1445-1449.

Research output: Contribution to journalArticle

@article{e42ef6bac78144aa821d09363a6db799,
title = "Living donor liver transplantation for hepatitis B associated liver diseases: A 10-year experience in a single center",
abstract = "Background/Aims: Hepatic failure associated with hepatitis B virus (HBV) is one of the main indications for living donor liver transplantation (LDLT). Methodology: Twenty-nine LDLTs, including liver cirrhosis due to HBV (LC-B) (n=17) and fulminant hepatitis B (FH-B) (n=12) were reviewed. Prophylaxis for reinfection was performed with a combination of lamivudine, or hepatitis B immune globulin (HBIG) or adefovir, depending on the viral status. The changes in serological markers, recurrence and survival rate were examined. Results: There were 3 patients with re-emergencies of HBV surface antigen (HBsAg): suspension of HBIG for giving vaccination for HBV (n=1), HBsAg positive donor (n=1) and non-compliance for HBIG (n=1). All patients with YMDD mutants (n=9), except the case with HBsAg positive donor (n=1), were successfully protected by the triple therapy of lamivudine, adefovir and HBIG. No graft loss was due to the recurrence of HBV. Conclusion: The basic strategy using a combination of HBIG and antiviral agents gave acceptable long-term outcomes for LDLT for HBV associated liver diseases. The close monitoring of HBV viral status after transplantation is still crucial in managing these patients.",
author = "Toru Ikegami and Yuji Soejima and Ryuji Ohta and Akinobu Taketomi and Tomoharu Yoshizumi and Noboru Harada and Hiroto Kayashima and Yoshihiko Maehara",
year = "2008",
month = "7",
day = "1",
language = "English",
volume = "55",
pages = "1445--1449",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "85",

}

TY - JOUR

T1 - Living donor liver transplantation for hepatitis B associated liver diseases

T2 - A 10-year experience in a single center

AU - Ikegami, Toru

AU - Soejima, Yuji

AU - Ohta, Ryuji

AU - Taketomi, Akinobu

AU - Yoshizumi, Tomoharu

AU - Harada, Noboru

AU - Kayashima, Hiroto

AU - Maehara, Yoshihiko

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Background/Aims: Hepatic failure associated with hepatitis B virus (HBV) is one of the main indications for living donor liver transplantation (LDLT). Methodology: Twenty-nine LDLTs, including liver cirrhosis due to HBV (LC-B) (n=17) and fulminant hepatitis B (FH-B) (n=12) were reviewed. Prophylaxis for reinfection was performed with a combination of lamivudine, or hepatitis B immune globulin (HBIG) or adefovir, depending on the viral status. The changes in serological markers, recurrence and survival rate were examined. Results: There were 3 patients with re-emergencies of HBV surface antigen (HBsAg): suspension of HBIG for giving vaccination for HBV (n=1), HBsAg positive donor (n=1) and non-compliance for HBIG (n=1). All patients with YMDD mutants (n=9), except the case with HBsAg positive donor (n=1), were successfully protected by the triple therapy of lamivudine, adefovir and HBIG. No graft loss was due to the recurrence of HBV. Conclusion: The basic strategy using a combination of HBIG and antiviral agents gave acceptable long-term outcomes for LDLT for HBV associated liver diseases. The close monitoring of HBV viral status after transplantation is still crucial in managing these patients.

AB - Background/Aims: Hepatic failure associated with hepatitis B virus (HBV) is one of the main indications for living donor liver transplantation (LDLT). Methodology: Twenty-nine LDLTs, including liver cirrhosis due to HBV (LC-B) (n=17) and fulminant hepatitis B (FH-B) (n=12) were reviewed. Prophylaxis for reinfection was performed with a combination of lamivudine, or hepatitis B immune globulin (HBIG) or adefovir, depending on the viral status. The changes in serological markers, recurrence and survival rate were examined. Results: There were 3 patients with re-emergencies of HBV surface antigen (HBsAg): suspension of HBIG for giving vaccination for HBV (n=1), HBsAg positive donor (n=1) and non-compliance for HBIG (n=1). All patients with YMDD mutants (n=9), except the case with HBsAg positive donor (n=1), were successfully protected by the triple therapy of lamivudine, adefovir and HBIG. No graft loss was due to the recurrence of HBV. Conclusion: The basic strategy using a combination of HBIG and antiviral agents gave acceptable long-term outcomes for LDLT for HBV associated liver diseases. The close monitoring of HBV viral status after transplantation is still crucial in managing these patients.

UR - http://www.scopus.com/inward/record.url?scp=58149382480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149382480&partnerID=8YFLogxK

M3 - Article

VL - 55

SP - 1445

EP - 1449

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 85

ER -